#USA #New York #Lung Cancer #Scientific Advisory Board #Lung Cancer Research Foundation

Expanding Horizons: LCRF Strengthens Scientific Advisory Board

Introduction

In a significant move to bolster its research initiatives, the Lung Cancer Research Foundation (LCRF) has announced the expansion of its Scientific Advisory Board (SAB) with the addition of five new esteemed members. This initiative aims to enhance the foundation's ability to support groundbreaking research and ultimately improve the outcomes for lung cancer patients. By reinforcing its leadership, LCRF is setting a course to double its research investments by the year 2030.

Background of the SAB

The Scientific Advisory Board plays a critical role in guiding LCRF's strategic research priorities. Comprised of many distinguished experts in the field, the SAB's function is to review, evaluate, and select impactful lung cancer research proposals for funding. According to Aubrey Rhodes, Executive Director of LCRF, the SAB is crucial in identifying innovative solutions and pioneering ideas that have the potential to transform lung cancer treatment.

New Additions to the Board

Led by Dr. Kathryn O'Donnell, Associate Professor of Molecular Biology at UT Southwestern Medical Center, the expanded SAB includes leaders renowned for their contributions to lung cancer research. The new members are:
1. Dr. Hossein Borghaei - Chief of Thoracic Medical Oncology at Fox Chase Cancer Center, who has been involved in numerous clinical trials aimed at developing antibody-based therapies and immunotherapies for lung cancer.
2. Dr. Matthew Bott - A thoracic surgeon at Memorial Sloan Kettering Cancer Center, noted for his expertise in robotic bronchoscopy and the treatment of lung and esophageal cancers.
3. Dr. Sanja Dacic - A Professor of Pathology at Yale School of Medicine, recognized for her research in diagnostic pulmonary and molecular pathology related to lung cancers.
4. Dr. Paul Hesketh - Director of the Lahey Cancer Institute and a notable figure in thoracic oncology with extensive experience in investigational therapeutics.
5. Dr. Misako Nagasaka - An Associate Clinical Professor at UCI School of Medicine who specializes in molecular targeted therapies and immunotherapy in thoracic malignancies.

The Importance of Junior Members

In addition to welcoming seasoned professionals, LCRF has introduced its first cohort of junior members to the SAB. These aspiring scientists will have the opportunity to review grant applications and serve as spokespersons for the foundation. This initiative highlights LCRF's commitment to nurturing the next generation of leaders in lung cancer research. Dhruba Deb, Senior Director of Research Programs at LCRF, noted that engaging junior members ensures that the research community is filled with innovative thinkers who can adapt to a rapidly changing landscape.

Funding and Future Goals

Historically, LCRF has allocated nearly $48 million towards lung cancer research, funding a total of 429 research grants thus far. With the strategic bolstering of its SAB, the foundation is focused on enhancing its research portfolio to include novel studies that could revolutionize treatment strategies for lung cancer patients.

Conclusion

The expansion of the Scientific Advisory Board by LCRF not only strengthens the foundation's leadership but also signifies a commitment to advancing research in lung cancer. By supporting groundbreaking discoveries and preparing future leaders in this vital field, LCRF is poised to make significant strides in improving survival and quality of life for patients affected by lung cancer. As LCRF embarks on this journey, its dedicated community continues to spearhead efforts for vital transformation in lung cancer research and care.

For further updates and insights, please visit LCRF.org/research.